Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwNHL 2017 | The role of epigenetic modulators in the pathogenesis of lymphomas

Anas Younes, Eduardo Sotomayor, Laura Pasqualucci and Owen O'Connor • 18 Sep 2017
iwNHL 2017
Non-Hodgkin Lymphoma

Anas Younes, MD, from the Memorial Sloan Kettering Cancer Center, New York, NY is joined by Eduardo Sotomayor, MD, from the George Washington University School of Medicine & Health Sciences, Washington, D.C, and Laura Pasqualucci, MD, from the Columbia University Medical Center, New York, NY, at the 2017 International Workshop in Non-Hodgkin Lymphoma (iwNHL) in Vancouver, BC, Canada. They discuss the results of large sequencing studies, and the role of epigenetic modulators in the pathogenesis of lymphomas.

More from Anas Younes

Fimepinostat with venetoclax in R/R lymphoma
1:01
Fimepinostat with venetoclax in R/R lymphoma
Anas Younes • 7 Dec 2019
Atezolizumab plus R-CHOP in DLBCL: encouraging results
1:27
Atezolizumab plus R-CHOP in DLBCL: encouraging results
Anas Younes • 7 Dec 2019
Dual inhibition of BCL2 and MCL1 using tumor targeted nanoparticles in lymphoma
1:42
Dual inhibition of BCL2 and MCL1 using tumor targeted nanoparticles in lymphoma
Anas Younes • 7 Dec 2019
Ibrutinib in combination with R-CHOP in DLBCL: does age make a difference?
2:55
Ibrutinib in combination with R-CHOP in DLBCL: does age make a difference?
Anas Younes • 6 Dec 2018

More from Laura Pasqualucci

New therapeutic targets in DLBCL
New therapeutic targets in DLBCL
Ash Alizadeh et al. • 17 Oct 2023
The lymphoma tumor microenvironment: therapeutic targeting, genetics, drug optimization
10:20
The lymphoma tumor microenvironment: therapeutic targeting, genetics, drug optimization
Laura Pasqualucci et al. • 17 Sep 2019
Panel discussion on large cell lymphomas: subtypes, patient selection and mutations
12:46
Panel discussion on large cell lymphomas: subtypes, patient selection and mutations
Andrew Zelenetz et al. • 23 Sep 2016

More from Owen O'Connor

Immunoepigenetic platforms for PTCL treatment
6:47
Immunoepigenetic platforms for PTCL treatment
Owen O'Connor • 2 Jul 2019
PTCL arising as a PTLD: the efficacy of pralatrexate
4:42
PTCL arising as a PTLD: the efficacy of pralatrexate
Owen O'Connor • 19 Jun 2019
iwNHL 2017: The future of lymphoma research and treatment
iwNHL 2017: The future of lymphoma research and treatment
Catherine Bollard et al. • 8 Sep 2017
TGR-1202, novel PI3K delta inhibitor, for hematological malignancies
5:45
TGR-1202, novel PI3K delta inhibitor, for hematological malignancies
Owen O'Connor • 3 Oct 2015

Related Videos

Exploring CAR-T and bispecifics in CLL: novel approaches beyond BTK and BCL2 inhibitors
2:30
Exploring CAR-T and bispecifics in CLL: novel approaches beyond BTK and BCL2 inhibitors
Alexey Danilov • 16 Oct 2026
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
2:39
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
Tina Bagratuni • 23 Sep 2026
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
2:13
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
Mary Jo Lechowicz • 11 Sep 2026
Key advances in FL management expected to change practice over the next five years
1:26
Key advances in FL management expected to change practice over the next five years
Kim Linton • 11 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals